FDA Review Manager Lumpkin Leaving Agency: Will Deadline Focus Survive?
This article was originally published in The Tan Sheet
Executive Summary
The resignation of Office of Review Management Director Murray Lumpkin, MD, will test whether FDA's tight focus on user fee goals can be maintained following the departure of the manager most directly responsible for overseeing the agency's performance against deadlines.
You may also be interested in...
Hiring Freeze Will Affect FDA Commissioner, ORM Director Appointments
Acting FDA Commissioner Bernard Schwetz, PhD, will continue to make funding the agency's science base a top priority, he stresses in a Jan. 22 email to agency staff.
Hiring Freeze Will Affect FDA Commissioner, ORM Director Appointments
Acting FDA Commissioner Bernard Schwetz, PhD, will continue to make funding the agency's science base a top priority, he stresses in a Jan. 22 email to agency staff.
Hiring Freeze Will Affect FDA Commissioner, ORM Director Appointments
Acting FDA Commissioner Bernard Schwetz, PhD, will continue to make funding the agency's science base a top priority, he stresses in a Jan. 22 email to agency staff.